A team of researchers
at Mayo
Clinic and The Scripps Research Institute in Florida have developed a new therapeutic strategy to
combat the most common genetic risk factor for the neurodegenerative disorders amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and frontotemporal dementia (FTD).